About PETAL Consortium
About PETAL Consortium
About PETAL Consortium
PETAL Consortium is a first-of-its-kind global network of more than 100 investigators dedicated to
improving outcomes for patients with peripheral T-cell lymphoma, a rare and aggressive blood cancer.
Since the disease is so rare, most studies are limited by small sample sizes in clinical trials. However,
PETAL Consortium addresses this challenge by connecting research sites across more than 20
countries. This collaborative network provides researchers access to hundreds of patients worldwide, helping to accelerate progress for this rare disease.
Founded and led by Salvia Jain, MD, an oncologist and hematologist at Mass General Brigham, PETAL
Consortium leverages cutting-edge artificial intelligence, machine learning, and genomics to drive scientific breakthroughs and advance the understanding of peripheral T-cell lymphoma.
At PETAL, we believe that education and empowerment are key to improving patient outcomes. To
support this mission, we launched HOPE-PTCL (Hub for Outreach and Patient Engagement in
Peripheral T-cell Lymphoma)–a patient-centered initiative that provides reliable information and support for patients, caregivers, families, and friends.
PETAL Consortium is a first-of-its-kind global network of more than 100 investigators dedicated to improving outcomes for patients with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Since the disease is so rare, most studies are limited by small sample sizes in clinical trials. However,
PETAL Consortium addresses this challenge by connecting research sites across more than 20 countries. This collaborative network provides researchers access to hundreds of patients worldwide, helping to accelerate progress for this rare disease.
Founded and led by Salvia Jain, MD, an oncologist and hematologist at Mass General Brigham, PETAL Consortium leverages cutting-edge artificial intelligence, machine learning, and genomics to drive scientific breakthroughs and advance the understanding of peripheral T-cell lymphoma.
At PETAL, we believe that education and empowerment are key to improving patient outcomes. To support this mission, we launched HOPE-PTCL (Hub for Outreach and Patient Engagement in Peripheral T-cell Lymphoma)–a patient-centered initiative that provides reliable information and support for patients, caregivers, families, and friends
PETAL Consortium is a first-of-its-kind global network of more than 100 investigators dedicated to
improving outcomes for patients with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Since the disease is so rare, most studies are limited by small sample sizes in clinical trials.
However, PETAL Consortium addresses this challenge by connecting research sites across more than 20 countries. This collaborative network provides researchers access to hundreds of patients worldwide, helping to accelerate progress for this rare disease.
Founded and led by Salvia Jain, MD, an oncologist and hematologist at Mass General Brigham, PETAL Consortium leverages cutting-edge artificial intelligence, machine learning, and genomics to drive scientific breakthroughs and advance the understanding of peripheral T-cell lymphoma.
At PETAL, we believe that education and empowerment are key to improving patient outcomes. To support this mission, we launched HOPE-PTCL (Hub for Outreach and Patient Engagement in
Peripheral T-cell Lymphoma)–a patient-centered initiative that provides reliable information and support for patients, caregivers, families, and friends
